Something is wrong down under. Infection rates at Australian hospitals have increased over the last few years, causing patients and medical professionals to call for hospitals to come clean with infection statistics. Wayne's
Molecular Detection Inc. hopes to lend a hand as they announced that the product rollout for its
Detect-Ready MRSA diagnosis platform would head to Australia this week, marking the start of a global sales strategy targeting the Asia-Pacific Corridor, parts of Europe and the United States. This strategy targets countries in need of infection prevention abroad before returning to the U.S. to set up a local base.
"(Australians) have the same problems in hospitals that we have here in the states," says MDI CEO Todd Wallach. "Patients are contracting MRSA and other bacterial infections in hospitals after a successful surgery or procedure. Many hospitals have to start implementing infection control procedures that identify patients at risk and force these hospitals to really look at how they take care of a patient from entry level to exit."
Aiding in MDI's transition into the Australian market is Sydney's
Integrated Sciences, a medical products and research company that, through a newly minted partnership with MDI, will aid Detect-Ready sales reps in chasing down leads and understanding the needs of the Aussie medical community.
"Our strategy has been very consistent around the world by identifying what we perceive as being the best-in-class, best-in-breed molecular diagnostic distributors," says Wallach. "They become our right-hand-man in the field. We work with them closely to ensure we get the right information conveyed but they bring the right skill set to be able to market a technically advanced product."
Source: Todd Wallach, MDI
Writer: John Steele